• By ICR Secretariat
  • Posted Tuesday, November 29, 2022

Infex begins study of pseudomonas aeruginosa candidate RESP-X

https://www.pharmatimes.com/news/infex_begins_study_of_pseudomonas_aeruginosa_candidate_resp-x_1481257

Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers

Infex – a company focusing on anti-infectives specialist – has announced that the first patients have been dosed in its phase 1 study researching candidate RESP-X.